{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:38:31Z","timestamp":1788349111289,"version":"build-2803163510"},"reference-count":65,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L003988\/1"],"award-info":[{"award-number":["MR\/L003988\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Community\u2019s Seventh Framework Programme","award":["279227"],"award-info":[{"award-number":["279227"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Biomedical Research Centre at South London"},{"name":"Maudsley NHS Foundation Trust"},{"name":"King\u2019s College London"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Treatment-resistant schizophrenia (TRS) is associated with alterations in glutamate levels and cerebral blood flow (CBF), and treatment with clozapine appears to have an impact on each of these measures. Here, we examined whether changes in CBF and glutamate levels following clozapine treatment are related.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Glutamate concentrations in the anterior cingulate cortex (ACC), and striatum (measured using proton magnetic resonance spectroscopy,\n                      <jats:sup>1<\/jats:sup>\n                      H-MRS); and whole brain regional CBF maps (measured using pseudo-continuous arterial spin labelling (pCASL)), were examined in a cohort of TRS subjects before and after 12 weeks of treatment with clozapine (baseline:\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 30; week 12:\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 20).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The longitudinal change in striatal glutamate during treatment was positively associated with the longitudinal change in striatal CBF (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.05). In the ACC, higher Glx (glutamate + glutamine) and CBF prior to treatment were associated with greater subsequent improvement in total symptom severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results indicate that there is a direct relationship between changes in glutamate activity and CBF in the striatum following clozapine treatment. Future research could investigate whether glutamate-CBF relationships exist in other stages of psychosis or schizophrenia and during treatment with other antipsychotic medications. Associations with clinical outcomes could be explored in larger samples.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251409141","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:48:21Z","timestamp":1767872901000},"page":"563-573","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Associations between glutamate and cerebral blood flow in treatment-resistant schizophrenia during clozapine treatment"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5532-3593","authenticated-orcid":false,"given":"Junyu","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Zelaya","sequence":"additional","affiliation":[{"name":"Department of Neuroimaging, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra-Verena","family":"Sendt","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"McQueen","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Warneford Hospital, University of Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lally","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"},{"name":"Department of Psychiatry, University College Dublin, Ireland"},{"name":"Department of Psychiatry, St Vincent\u2019s Hospital Fairview, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"O\u2019Daly","sequence":"additional","affiliation":[{"name":"Department of Neuroimaging, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Lythgoe","sequence":"additional","affiliation":[{"name":"Department of Neuroimaging, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5214-7421","authenticated-orcid":false,"given":"Gareth J.","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Neuroimaging, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McGuire","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Warneford Hospital, University of Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-1018","authenticated-orcid":false,"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"},{"name":"National Psychosis Unit, South London and Maudsley NHS Foundation Trust, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Egerton","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.25197"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)38228-X"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)37013-2"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09613"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00022"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00632"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2002.87.5.2324"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.289"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2010.07.017"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2014.07.016"},{"issue":"3","key":"e_1_3_3_12_1","first-page":"438","article-title":"Volumetric changes in the basal ganglia after antipsychotic monotherapy: A systematic review","volume":"20","author":"Ebdrup BH","year":"2013","unstructured":"Ebdrup BH, N\u00f8rbak H, Borgwardt S, et al. (2013) Volumetric changes in the basal ganglia after antipsychotic monotherapy: A systematic review. Current Medicinal Chemistry 20(3): 438\u2013447.","journal-title":"Current Medicinal Chemistry"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2017.00066"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0082-9"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.113"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2020.09.013"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscychresns.2009.04.007"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)00040-1"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000148636.60732.2e"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom9060234"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.20901"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00769-8"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2014.03.014"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145708009085"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(95)71666-8"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.05.016"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.830757"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-015-0650-9"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.644315"},{"issue":"1","key":"e_1_3_3_32_1","first-page":"13","article-title":"Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia","volume":"8","author":"Krajner F","year":"2022","unstructured":"Krajner F, Hadaya L, McQueen G, et al. (2022) Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia. Schizophrenia (Heidelberg, Germany) 8(1): 13.","journal-title":"Schizophrenia (Heidelberg, Germany)"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2013.12.062"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.923076"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2020.03.069"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01602-5"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301325"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06976"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301356"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(96)00546-X"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2015.11.002"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-4997-2"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaa156"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.0442"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-01991-7"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.0380"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)01001-5"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4428"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01297-6"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2022.110669"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.1910300604"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033412"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.2.79"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24833-y"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13361"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00754"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-024-00544-3"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1226740"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1623"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00406-6"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2016.172"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.593703"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.105010"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-023-01515-0"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.2190\/1AA0-UW9Q-1CNK-3E2N"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn980"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251409141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251409141","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251409141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:16:59Z","timestamp":1782159419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251409141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/02698811251409141"],"URL":"https:\/\/doi.org\/10.1177\/02698811251409141","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}